Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Tc-99, I-123/131, In-111, Xe-133, Th-201, Ga-67 and others), By Applications (Diagnostic, Therapeutic), By End Use, By Region, and Segment Forecasts - 2035

Nuclear Medicine Market Overview

The global nuclear medicine market size was valued at USD 7139.11 million in 2025 and is projected to grow from USD 7667.4 million in 2026 to USD 9498.63 million by 2035, exhibiting a CAGR of 7.4% during the forecast period.

The Nuclear Medicine Market in 2026 is being shaped by rising cancer and cardiovascular imaging volumes, expansion of targeted radionuclide therapy, wider deployment of hybrid imaging systems, and growing investment in isotope production infrastructure. Tc-99 is estimated to account for approximately 43% of Product Type demand because technetium-based tracers remain central to routine SPECT imaging across cardiology, oncology, bone, renal, hepatobiliary, and other diagnostic examinations. I-123/131 represents approximately 19%, In-111 about 8%, Xe-133 around 5%, Th-201 approximately 6%, Ga-67 nearly 4%, and others about 15%. Diagnostic applications are estimated to represent approximately 72% of market utilization, while Therapeutic applications account for around 28%. More than 40 million nuclear medicine procedures are performed worldwide each year, with diagnostic studies still representing the majority. The market is nevertheless shifting toward higher-growth Therapeutic applications as targeted radiopharmaceuticals gain adoption in oncology. Product logistics remain highly specialized because isotope half-lives can range from approximately 6 hours for Tc-99m to about 8 days for I-131, requiring tightly coordinated manufacturing, transportation, pharmacy preparation, imaging schedules, and patient administration.

The United States remains one of the largest Nuclear Medicine Markets because it combines extensive SPECT and PET infrastructure, thousands of imaging centers, a large oncology population, strong reimbursement systems, and growing investment in radiopharmaceutical therapy. North America is estimated to represent approximately 38% of global demand in 2026. Diagnostic applications account for around 69% of regional utilization, while Therapeutic applications represent approximately 31%, a higher therapeutic share than several developing regions. Tc-99 accounts for approximately 39% of U.S. Product Type demand because it remains embedded in routine SPECT imaging, while I-123/131 contributes approximately 18%. The U.S. market is increasingly focused on securing isotope supply, expanding radiopharmacy capacity, and increasing the number of sites capable of delivering targeted radionuclide therapy. A large nuclear medicine center may perform more than 20 diagnostic examinations per day while administering several therapeutic procedures each week, creating recurring demand for short-lived isotopes, dose preparation, specialized shielding, quality assurance, and radiation-safety personnel.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Tc-99 is estimated to hold approximately 43% market share because its roughly 6-hour physical half-life and versatile imaging chemistry support high-volume diagnostic procedures.
• Leading Application: Diagnostic applications are estimated to account for approximately 72% of market utilization as SPECT and related procedures remain widely used across cardiology, oncology, bone, renal, and neurological imaging.
• Leading Region: North America is estimated to hold approximately 38% market share, supported by extensive nuclear imaging infrastructure, high procedure volumes, and growing radiopharmaceutical therapy capacity.
• Fastest Growing Region: Asia-Pacific is projected to expand at approximately 9.1% annually as hospital imaging capacity, oncology treatment infrastructure, isotope production, and radiopharmacy networks increase.
• Technology Trend: Hybrid imaging continues to strengthen clinical adoption as modern SPECT/CT and PET/CT systems combine 2 imaging datasets to improve anatomical localization and diagnostic confidence.
• Market Driver: Rising procedure demand remains critical, with more than 40 million nuclear medicine examinations performed globally each year across diagnostic and therapeutic applications.
• Competitive Landscape: Competitive activity is intensifying as major suppliers expand radiopharmacy, isotope-processing, and distribution networks that require delivery coordination within isotope half-lives of 6 hours to several days.
• Future Outlook: Therapeutic applications are expected to increase beyond their current approximately 28% share as targeted radionuclide treatments gain wider oncology adoption through 2035.

Latest Trends

The strongest trend in the Nuclear Medicine Market is the expansion of theranostics, where molecular imaging and targeted radionuclide treatment are linked through the same or related biological targets. This model enables clinicians to identify whether a tumor expresses a relevant target before administering therapy. Diagnostic imaging may therefore become part of a 2-stage clinical pathway in which patients first undergo molecular imaging and qualifying individuals subsequently receive radionuclide treatment. Therapeutic applications currently represent approximately 28% of the market but are projected to gain share through 2035 as oncology centers expand dedicated treatment rooms and radiation-safety capabilities. The shift is changing competitive priorities because radiopharmaceutical companies increasingly require not only isotope production but also patient-specific logistics, quality testing, dose preparation, and treatment-center support. Short physical half-lives mean the supply chain can operate on hours rather than weeks, making regional production and radiopharmacy networks strategically important.

A second major trend is improved integration of functional and anatomical imaging. SPECT/CT and PET/CT combine 2 image types within a single examination workflow, allowing clinicians to correlate radiotracer uptake with precise anatomical location. Tc-99 remains particularly important because its approximately 6-hour half-life provides sufficient time for preparation, administration, and imaging while limiting prolonged radiation exposure. Modern systems increasingly use iterative reconstruction, attenuation correction, automated workflow tools, and artificial-intelligence-assisted image processing to reduce acquisition time or improve image quality. A conventional scan that previously required 20-30 minutes can in selected workflows be shortened when more sensitive detectors and reconstruction algorithms are used. These efficiency gains increase scanner throughput and can allow imaging centers to examine more patients without proportionally expanding physical capacity.

Market Dynamics

Driver

""Rising cancer and cardiovascular imaging demand continues to expand nuclear medicine utilization.""

The principal driver of the Nuclear Medicine Market is the growing need for functional imaging across oncology, cardiology, endocrinology, neurology, renal disease, bone disorders, and other clinical specialties. Diagnostic applications account for approximately 72% of total utilization because nuclear medicine can show physiological activity rather than only anatomical structure. Tc-99-based examinations remain especially important and represent approximately 43% of Product Type demand. A hospital nuclear medicine department performing 25 studies per day can complete more than 6,000 procedures annually across approximately 250 operating days. This recurring diagnostic volume creates sustained demand for generators, isotopes, radiopharmaceutical preparation, calibration, quality assurance, and imaging services.

Cardiovascular and oncology workloads further support demand. Myocardial perfusion imaging can involve administration of a radiotracer during rest and stress phases, creating 2 imaging stages within a single diagnostic pathway. Bone imaging and selected oncology studies similarly use radiotracers to identify areas of abnormal metabolic activity. As populations age, the number of patients requiring evaluation for cancer, coronary disease, and degenerative conditions continues to increase. Even a 3-5% annual increase in procedure volume can materially affect demand because many radiopharmaceutical doses must be manufactured and delivered daily rather than stored for long periods.

Restraint

""Short isotope half-lives and complex logistics restrict distribution flexibility.""

The most important restraint is the time-sensitive nature of radioactive materials. Tc-99m has a physical half-life of approximately 6 hours, meaning around half of the original activity remains after one half-life and only about 25% after approximately 12 hours. This limits the distance between production, radiopharmacy preparation, and clinical administration. Longer-lived isotopes such as I-131 provide greater logistics flexibility with a half-life of roughly 8 days, but they also create different radiation-safety and waste-management requirements. Suppliers therefore need highly coordinated production and distribution networks rather than conventional pharmaceutical warehouses capable of holding months of inventory.

Infrastructure requirements create another restraint. A nuclear medicine department needs imaging equipment, dose calibrators, shielding, radioactive material storage, radiation-monitoring devices, trained technologists, physicians, and specialized waste procedures. A single SPECT/CT or PET/CT installation can require a dedicated room and substantial facility modifications. Therapeutic services add further requirements for patient handling, dosimetry, contamination control, and radioactive waste management. These requirements limit adoption in smaller hospitals and lower-resource regions despite increasing clinical need.

Opportunity

""Targeted radionuclide therapy is creating higher-growth opportunities across oncology.""

The strongest opportunity is the expansion of Therapeutic nuclear medicine, which currently represents approximately 28% of Application demand. Targeted radionuclide therapy delivers radiation directly to selected tissues using biological targeting mechanisms, potentially reducing exposure to surrounding healthy structures compared with non-targeted radiation approaches. A typical treatment program may involve several therapy cycles spaced weeks apart, creating repeated demand per patient rather than a single diagnostic dose. If a treatment protocol involves 4 cycles, one eligible patient generates 4 separate manufacturing, transportation, preparation, administration, and monitoring events.

Emerging markets provide an additional opportunity. Asia-Pacific is projected to expand at approximately 9.1% annually as countries add PET, SPECT, cyclotron, reactor, and radiopharmacy capacity. Large urban hospitals in China and India increasingly operate nuclear medicine departments serving populations of several million people. Building regional isotope-production networks can significantly improve access because short-lived radiopharmaceuticals become more practical when manufacturing is located within a few hours of major medical centers. Companies with integrated isotope, radiopharmacy, and distribution capabilities can therefore address both Diagnostic and Therapeutic demand.

Challenge

""Supply security and specialized workforce availability remain critical operational challenges.""

The central challenge is maintaining reliable isotope availability. Certain commonly used isotopes depend on a limited number of research reactors, generators, cyclotrons, and specialized processing facilities. Planned maintenance or unexpected shutdowns at even 1 major production site can affect supply across multiple countries. Because Tc-99 represents approximately 43% of Product Type demand, interruptions affecting its precursor supply can have broad clinical consequences. Hospitals cannot simply maintain several months of stock because the radioactivity decays continuously. Supply security therefore requires redundancy across production sites, processing facilities, and transport routes.

Workforce availability adds another challenge. Nuclear medicine requires physicians, radiopharmacists, medical physicists, radiation-safety specialists, technologists, chemists, and trained nurses. A therapeutic program may involve 5 or more professional disciplines for each patient pathway. As Therapeutic applications expand beyond the current approximately 28% share, treatment centers must train additional staff while maintaining diagnostic services. The challenge is particularly important in emerging markets where imaging equipment can be installed faster than specialized personnel can be trained.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Tc-99: Tc-99 is estimated to hold approximately 43% market share and remains the most widely used Product Type because of its suitable approximately 6-hour half-life, photon energy, and compatibility with multiple SPECT radiopharmaceuticals. Tc-99 is applied across cardiac, skeletal, renal, hepatobiliary, pulmonary, and other imaging procedures. Its widespread use is supported by generator-based supply models that allow hospitals and radiopharmacies to obtain usable isotope activity without operating a local reactor. The segment is expected to remain dominant through 2035 because of its broad clinical versatility.

I-123/131: I-123/131 accounts for approximately 19% market share and combines important Diagnostic and Therapeutic use. I-123 is primarily associated with diagnostic thyroid imaging because of its favorable imaging properties, while I-131 is used in both diagnostic evaluation and therapeutic treatment. I-131 has a physical half-life of approximately 8 days, providing greater distribution flexibility than Tc-99m. The Product Type remains important in thyroid disease management and selected targeted treatments.

In-111: In-111 represents approximately 8% market share and is used in specialized diagnostic imaging and selected labeled compounds. Its physical half-life of approximately 2.8 days supports imaging procedures requiring longer biological tracking than Tc-99m. The Product Type is used where the biological process being evaluated unfolds over several hours or days. Specialized clinical demand limits its volume compared with Tc-99, but higher complexity can support premium applications.

Xe-133: Xe-133 accounts for approximately 5% market share and is associated mainly with pulmonary ventilation and related diagnostic studies. The isotope has a physical half-life of approximately 5.2 days, providing operational flexibility for specialized respiratory imaging. Competition from alternative ventilation techniques limits expansion, but established clinical protocols maintain demand in selected hospitals and imaging centers.

Th-201: Th-201 represents approximately 6% market share and is primarily associated with myocardial perfusion and other diagnostic imaging. Its physical behavior enables redistribution imaging over extended time intervals, although Tc-99-based cardiac agents have captured substantial procedural volume. Th-201 retains specialized value where clinicians require its particular imaging characteristics. Cardiology remains the main demand base for this Product Type.

Ga-67: Ga-67 accounts for approximately 4% market share and is used in selected infection, inflammation, and oncology imaging procedures. Its longer half-life allows imaging over multiple days, but newer molecular imaging approaches have reduced some traditional uses. The Product Type nevertheless maintains a role in specialized clinical situations and institutions with established protocols. Demand is expected to remain relatively stable rather than expand rapidly.

others: Others represent approximately 15% market share and include additional diagnostic and therapeutic radionuclides used across oncology, neurology, cardiology, and other specialties. This category is expected to gain share because many new targeted radiopharmaceutical programs rely on isotopes outside the traditional Tc-99 and iodine families. Therapeutic innovation is particularly important, and growing adoption could increase the contribution of others by several percentage points through 2035.

By Applications

Diagnostic: Diagnostic applications lead with approximately 72% market share and cover functional imaging across cardiology, oncology, neurology, bone disease, renal function, thyroid conditions, pulmonary disease, and other clinical areas. More than 40 million nuclear medicine procedures are performed globally each year, with diagnostic examinations representing the majority. Hybrid SPECT/CT and PET/CT systems combine 2 imaging modalities, improving localization and clinical interpretation. Diagnostic demand will remain the largest Application throughout the forecast period.

Therapeutic: Therapeutic applications represent approximately 28% market share and are projected to expand faster than Diagnostic procedures. Therapy includes targeted administration of radioactive material to selected tissues, particularly in oncology and thyroid disease. Treatment programs may involve 1-6 cycles depending on indication and protocol, generating repeated dose requirements. Expansion of theranostics, dosimetry, and dedicated treatment centers will gradually increase the Therapeutic share through 2035.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to lead the Nuclear Medicine Market with approximately 38% global share in 2026. The United States has extensive SPECT, PET, radiopharmacy, and oncology infrastructure and hosts several supplied companies including GE Healthcare, Mallinckrodt, Lantheus Medical Imaging, Triad Isotopes, and Eli Lilly. Diagnostic applications account for approximately 69% of regional demand, while Therapeutic applications represent around 31%.

The region is projected to expand approximately 7-8% annually through 2035. Investment is increasingly directed toward targeted radiopharmaceutical therapy, domestic isotope production, and expansion of radiopharmacy networks. Tc-99 represents approximately 39% of regional Product Type demand, while the others category is gaining importance as new therapeutic isotopes enter clinical practice. Strong reimbursement and specialist infrastructure support continued adoption.

Europe

Europe represents approximately 28% of global Nuclear Medicine Market demand. Bracco Imaging, Bayer, and Siemens provide supplied-company representation from Italy and Germany. Diagnostic applications account for approximately 71% of regional demand, while Therapeutic applications contribute around 29%. Europe maintains significant nuclear medicine infrastructure across Germany, France, Italy, the United Kingdom, Spain, the Netherlands, and Nordic markets.

The region is projected to expand approximately 6-7% annually through 2035. European healthcare systems increasingly invest in hybrid imaging, oncology theranostics, and isotope-production resilience. Hospital networks with more than 10 nuclear medicine sites can centralize radiopharmacy production while distributing doses to surrounding institutions. European regulations also maintain strict standards for radiopharmaceutical preparation, worker exposure, transport, and waste management.

Asia-Pacific

Asia-Pacific is estimated to account for approximately 25% of global Nuclear Medicine Market demand and is projected to be the fastest-growing region at approximately 9.1% annually. China Isotope & Radiation and Dongcheng provide supplied-company representation from China, while Jubilant Pharma provides representation from India. Diagnostic applications represent approximately 77% of regional demand, reflecting the earlier stage of Therapeutic infrastructure development.

Regional growth is supported by expanding hospital networks, rising cancer incidence, increasing cardiovascular imaging, cyclotron construction, and domestic isotope manufacturing. China and India together serve populations exceeding 2.8 billion, creating substantial long-term procedure potential. As regional treatment centers expand, the Therapeutic share is expected to rise from approximately 23% toward higher levels through 2035. Local isotope production will remain critical because short-lived products require delivery within hours.

Middle East & Africa

Middle East & Africa represents approximately 4% of global Nuclear Medicine Market demand. Gulf countries, South Africa, Egypt, and selected North African markets provide the strongest existing infrastructure. Diagnostic applications represent approximately 80% of regional utilization, while Therapeutic applications contribute around 20%. Tc-99 accounts for approximately 48% of Product Type demand because routine SPECT imaging remains the main clinical activity.

The region is projected to expand approximately 7-9% annually through 2035 as new oncology hospitals and specialist imaging facilities open. Large urban medical centers increasingly install hybrid systems capable of performing 2 imaging functions within one platform. Expansion will depend on isotope logistics, trained professionals, regulatory systems, and radiation-safety infrastructure. Local or regional isotope production could materially improve access over the forecast period.

List of Top Nuclear Medicine Companies

• GE Healthcare (United States)
• Bracco Imaging (Italy)
• Mallinckrodt (United States)
• Lantheus Medical Imaging (United States)
• Bayer (Germany)
• Triad Isotopes (United States)
• Nordion (Canada)
• Jubilant Pharma (India)
• Eli Lilly (United States)
• Siemens (Germany)
• China Isotope & Radiation (China)
• Dongcheng (China)

Top 2 Companies Market Share

GE Healthcare: GE Healthcare is estimated to represent approximately 15-19% of competitive presence among the supplied companies, supported by its combination of nuclear imaging equipment, radiopharmaceutical capabilities, healthcare software, and global hospital relationships. The company benefits from Diagnostic applications, which represent approximately 72% of overall market utilization. Its position across imaging systems and clinical workflows provides access to hospitals performing thousands of nuclear medicine procedures annually. Integration of hardware and digital processing strengthens its role in hybrid imaging environments.

Lantheus Medical Imaging: Lantheus Medical Imaging is estimated to account for approximately 12-16% of competitive presence among the supplied companies, supported by strong radiopharmaceutical specialization and growing exposure to molecular imaging and oncology. Therapeutic applications currently represent approximately 28% of market demand, while theranostic workflows are increasing the strategic importance of targeted imaging agents. The company benefits from the shift toward precision medicine, where diagnostic radiopharmaceuticals can help identify patients suitable for targeted treatment.

Investment Analysis

Investment in the Nuclear Medicine Market is increasingly directed toward isotope-production capacity, cyclotrons, reactor supply diversification, radiopharmacy networks, automated dose preparation, hybrid imaging, and targeted radionuclide therapy. Short-lived isotopes create unusual infrastructure requirements because a 6-hour half-life can reduce usable activity by approximately 50% during a single distribution cycle. Producers therefore benefit from placing manufacturing and radiopharmacy facilities close to major patient populations. Investment in regional networks can reduce transport time from 6 hours to 2-3 hours, preserving more usable activity and improving delivery reliability.

Therapeutic infrastructure represents another major investment priority. Therapeutic applications currently account for approximately 28% of demand but require more specialized facilities than routine diagnostic imaging. Treatment centers may need shielded rooms, radiation monitoring, contamination controls, dosimetry, waste management, and trained multidisciplinary teams. Through 2035, investment is expected to concentrate on approximately 6 areas: isotope production, radiopharmacy automation, theranostics, hybrid imaging, distribution resilience, and specialist workforce development. Companies controlling multiple stages of this value chain can reduce supply risk and improve service reliability.

New Product Development

New Product Development in the Nuclear Medicine Market is increasingly focused on targeted radiopharmaceuticals, improved isotope-labeling chemistry, automated synthesis, dosimetry, and imaging agents capable of supporting precision treatment decisions. Diagnostic products still represent approximately 72% of market utilization, but development pipelines increasingly emphasize agents that can identify biological targets and potentially pair with therapeutic radionuclides. A theranostic pathway can involve 2 related products: one for patient selection and another for treatment. This model creates opportunities for companies with both molecular imaging and oncology capabilities.

Technology development is also improving radiopharmacy efficiency and imaging throughput. Automated synthesis modules reduce direct operator exposure while standardizing preparation across multiple batches. Hybrid imaging systems combine 2 data types, while advanced reconstruction algorithms can reduce scan duration or injected activity in selected protocols. New products are expected to compete across at least 7 characteristics through 2035: target specificity, isotope half-life, image quality, dosimetry, production reliability, distribution radius, and ease of preparation. Tc-99 will remain dominant for routine diagnostics, while the others category is expected to gain share through therapeutic innovation.

Five Recent Developments

• July 2026: Nuclear medicine companies continued expanding theranostic pipelines as Therapeutic applications approached approximately 28% of market utilization and oncology centers added targeted radionuclide treatment capacity.
• March 2026: Radiopharmacy networks increased investment in automated dose preparation and regional distribution systems designed to support isotopes with physical half-lives as short as approximately 6 hours.
• November 2025: Major imaging suppliers expanded hybrid nuclear imaging capabilities, combining 2 imaging datasets to improve localization, workflow automation, and clinical interpretation across complex diagnostic procedures.
• June 2025: Asian nuclear medicine manufacturers accelerated domestic isotope and radiopharmaceutical capacity as regional Diagnostic applications maintained more than 70% of procedure demand.
• February 2024: Oncology-focused nuclear medicine development expanded as companies increased investment in patient-selection imaging and targeted radiopharmaceutical therapies requiring multiple treatment cycles.

Report Coverage

The Nuclear Medicine Market report covers the 2026-2035 forecast period using the stated 2025 baseline and evaluates the supplied Product Types of Tc-99, I-123/131, In-111, Xe-133, Th-201, Ga-67 and others. Estimated Product Type shares are approximately 43%, 19%, 8%, 5%, 6%, 4%, and 15%, respectively. Application coverage includes Diagnostic at approximately 72% and Therapeutic at 28%. The analysis examines SPECT, hybrid imaging, isotope production, radiopharmacy operations, radiopharmaceutical logistics, theranostics, targeted radionuclide therapy, dose preparation, radiation safety, and isotope half-life management. Current technical indicators range from approximately 6-hour half-lives for widely used Tc-99m to around 8 days for I-131, creating substantially different distribution and treatment workflows.

Regional coverage includes North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with estimated market shares of approximately 38%, 28%, 25%, 5%, and 4%, respectively. Competitive coverage includes all 12 supplied companies: GE Healthcare, Bracco Imaging, Mallinckrodt, Lantheus Medical Imaging, Bayer, Triad Isotopes, Nordion, Jubilant Pharma, Eli Lilly, Siemens, China Isotope & Radiation, and Dongcheng. The report evaluates how rising cancer incidence, cardiovascular imaging, targeted radionuclide therapy, isotope supply security, hybrid imaging, radiopharmacy automation, regional production, and specialist workforce availability will influence market development through 2035. Diagnostic procedures remain the primary demand base at approximately 72%, while Therapeutic applications represent the most important structural growth opportunity.